CR10261A - Formulaciones novedosas - Google Patents

Formulaciones novedosas

Info

Publication number
CR10261A
CR10261A CR10261A CR10261A CR10261A CR 10261 A CR10261 A CR 10261A CR 10261 A CR10261 A CR 10261A CR 10261 A CR10261 A CR 10261A CR 10261 A CR10261 A CR 10261A
Authority
CR
Costa Rica
Prior art keywords
formulations
new formulations
fpf
variability
therapy
Prior art date
Application number
CR10261A
Other languages
English (en)
Inventor
John Capecchi
James Stefely
Trevor Riley
Original Assignee
3M Innovative Properties Co
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38523271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10261(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 3M Innovative Properties Co, Glaxo Group Ltd filed Critical 3M Innovative Properties Co
Publication of CR10261A publication Critical patent/CR10261A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/23—Solid substances, e.g. granules, powders, blocks, tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a formulaciones farmacéuticas novedosas en aerosol, procedimientos para su preparación, su uso en terapia, inhaladores de dosis medida que contiene dichas formulaciones y el uso de polimeros biocompatibles para reducir la variabilidad de la uniformidad de contenido y/o para proporcionar fracción de particula fina (FPF) mejorada en dichas formulaciones.
CR10261A 2006-03-22 2008-08-28 Formulaciones novedosas CR10261A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78463406P 2006-03-22 2006-03-22

Publications (1)

Publication Number Publication Date
CR10261A true CR10261A (es) 2008-11-26

Family

ID=38523271

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10261A CR10261A (es) 2006-03-22 2008-08-28 Formulaciones novedosas

Country Status (18)

Country Link
EP (1) EP2012797A2 (es)
JP (1) JP2009530419A (es)
KR (1) KR20080110854A (es)
CN (1) CN101415428A (es)
AR (1) AR060039A1 (es)
AU (1) AU2007226899A1 (es)
BR (1) BRPI0708798A2 (es)
CA (1) CA2646236A1 (es)
CR (1) CR10261A (es)
EA (1) EA200801854A1 (es)
IL (1) IL193723A0 (es)
MA (1) MA30328B1 (es)
MX (1) MX2008011967A (es)
NO (1) NO20083760L (es)
PE (1) PE20080124A1 (es)
TW (1) TW200803870A (es)
WO (1) WO2007109698A2 (es)
ZA (1) ZA200807682B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3578169T (pt) * 2009-02-26 2024-07-29 Glaxo Group Ltd Formulações farmacêuticas compreendendo 4-{(1r)-2-[(2,6- diclorobenzil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2- (hidroximetil)fenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679511B2 (en) * 1993-03-17 1997-07-03 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
BRPI0113042B8 (pt) * 2000-08-05 2021-05-25 Glaxo Group Ltd composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato

Also Published As

Publication number Publication date
ZA200807682B (en) 2009-11-25
CA2646236A1 (en) 2007-09-27
PE20080124A1 (es) 2008-04-21
EA200801854A1 (ru) 2009-04-28
EP2012797A2 (en) 2009-01-14
JP2009530419A (ja) 2009-08-27
TW200803870A (en) 2008-01-16
WO2007109698A2 (en) 2007-09-27
NO20083760L (no) 2008-12-17
MA30328B1 (fr) 2009-04-01
BRPI0708798A2 (pt) 2011-06-14
IL193723A0 (en) 2009-08-03
WO2007109698A3 (en) 2008-12-18
AU2007226899A1 (en) 2007-09-27
CN101415428A (zh) 2009-04-22
AR060039A1 (es) 2008-05-21
KR20080110854A (ko) 2008-12-19
MX2008011967A (es) 2009-01-14

Similar Documents

Publication Publication Date Title
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
ECSP088403A (es) Formulacion farmaceutica de absorción oral y su método de administracion
BR112012007182A2 (pt) uso de um material arrastado em dessecante, válvula de dosagem de inalador pressurizado de dose medida, sistema de recipiente fechado de inalador pressurizado de dose medida, e, método para estabilizar a massa de partícula fina (mpf) de uma formulação de droga de inalação
NZ588913A (en) Liver cancer drug
MX2007008379A (es) Metodos y composiciones para minimizar la acumulacion de insulina inhlable en los pulmones.
SG160364A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
EA200801213A1 (ru) Игла для прокалывания капсул с порошком для ингаляции
MX336225B (es) Composiciones que comprenden sulfato de salbutamol.
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
CR10112A (es) Enmascaramiento del sabor de polvos.
UA101652C2 (uk) Композиція для інгаляції, що містить аклідиній для лікування астми та хронічного обструктивного захворювання легень
GB2496799A (en) A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
BR112014008602A2 (pt) composição farmacêutica, recipiente vedado, inalador de dosagem medida, métodos para o tratamento de um paciente que sofre ou provavelmente sofre de um distúrbio respiratório, e, método para fabricação de uma composição farmacêutica
EA201401354A1 (ru) Новая дозированная форма и препарат, содержащий абедитерол
WO2012040228A3 (en) Aerosol composition for administering drugs
BR112015026053A8 (pt) composição farmacêutica, recipiente vedado, inalador dosimetrado, uso de um componente propelente, e, método para fabricação de uma composição farmacêutica
CY1117596T1 (el) Φαρμακευτικeς συνθeσεις αερολyματος φορμοτερολης και διπροπιονικης βεκλομεθαζονης
MX2015015150A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
CR10261A (es) Formulaciones novedosas
AR083893A1 (es) Uso de una composicion farmaceutica que comprende (s) (3-(1-(1h-imidazol-4-il)etil)-2-metilfenil)metanol para preparar un medicamento topico de utilidad en la reduccion de la presion intraocular y articulo de manufactura correspondiente
MX2010007569A (es) Productos farmaceuticos para inhalacion, sistemas y usos.
UA109530C2 (uk) Композиції, способи та системи для доставки респіраторним шляхом двох чи більше активних агентів

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)